Nucleix Ltd. Revenue and Competitors

Rehovot,

Location

$83M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Nucleix Ltd.'s estimated annual revenue is currently $12.9M per year.(i)
  • Nucleix Ltd.'s estimated revenue per employee is $155,000
  • Nucleix Ltd.'s total funding is $83M.

Employee Data

  • Nucleix Ltd. has 83 Employees.(i)
  • Nucleix Ltd. grew their employee count by 8% last year.

Nucleix Ltd.'s People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Co-founder, VP Software & AnalyticsReveal Email/Phone
3
Co-founder, VP ResearchReveal Email/Phone
4
VP Product DevelopmentReveal Email/Phone
5
VP, Clincal AffairsReveal Email/Phone
6
VP Sales & Marketing EMEA, APAC & LATAMReveal Email/Phone
7
VP MedicalReveal Email/Phone
8
Chief Financial OfficerReveal Email/Phone
9
Associate Director, Laboratory OperationsReveal Email/Phone
10
Senior Director, Clinical OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Nucleix Ltd.?

Nucleix is a global leader in creating cancer diagnostic panels based on epigenetic bio markers. Backed by OrbiMed and other leading investors, Nucleix provides a strong pipeline of products for various cancer types.

keywords:N/A

$83M

Total Funding

83

Number of Employees

$12.9M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Nucleix Ltd. News

2021-04-08 - Liquid biopsy maker Nucleix rakes in $55M to develop blood tests to detect lung cancer early

It’s full steam ahead for Nucleix’s blood test for lung cancer detection, thanks to an influx of cash in the Israeli company’s latest round of funding. Free Infographic Download 7 Areas to Evaluate When Selecting Your Clinical Adjudication Partner Clinical trials can include an independent unb ...

2021-04-07 - Nucleix Nabs $55M For Lung Cancer Detection

San Diego-based Nucleix, a startup which is developing liquid biopsy technology for early detection of lung cancer, has raised $55M in a funding round, the company announced this morning. The company said the funding was led by RA Capital Management, and also included BlackRock, Lilly Asia Ventu ...

2021-04-07 - Nucleix Secures $55M in Funding

Nucleix, a Rehovot, Israel- and San Diego, CA-based liquid biopsy company, secured $55m in funding. The round was led by RA Capital Management, with participation from new investors including funds and accounts managed by BlackRock, Lilly Asia Ventures, LYFE Capital and MILFAM. Existing investo ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.9M832%N/A
#2
$13.5M874%N/A
#3
$25.9M103-10%N/A
#4
$35.1M10824%N/A
#5
$32.4M120-10%N/A